In a decision closely watched by parents and teachers across America, a panel of independent experts advising the U.S. Food and Drug Administration on Oct. 26 recommended that regulators authorize Pfizer’s COVID-19 vaccine for 5-year-olds to 11-year-olds, a group that numbers 28 million.
